Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology

Clin Pharmacol Ther. 2020 Oct;108(4):699-702. doi: 10.1002/cpt.1879. Epub 2020 May 28.

Abstract

The unprecedented challenges posed by the coronavirus disease 2019 (COVID-19) pandemic highlight the urgency for applying clinical pharmacology and model-informed drug development in (i) dosage optimization for COVID-19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non-COVID-19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development, and regulation.

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Clinical Trials as Topic / methods*
  • Clinical Trials as Topic / standards
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Drug Development / methods*
  • Drug Development / standards
  • Humans
  • Pandemics / prevention & control*
  • Pharmacology, Clinical / methods*
  • Pharmacology, Clinical / standards
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • SARS-CoV-2